ClinicaliQ Trial Snapshot
- TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO — Recruiting • Oncology • NCT05628376.
- What is being tested: TRACERx EVO tracks tumour evolution and genetic changes throughout treatment in patients with early- and late-stage NSCLC, SCLC, and pleural mesothelioma using a prospective observational cohort approach.
- Patient eligibility overview: The study recruits individuals diagnosed with non-small cell lung cancer, small cell lung cancer, or pleural mesothelioma across all disease stages, enabling comprehensive analysis of disease progression patterns.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
Eligibility Snapshot
- : * Cohort A, B and C : * Written Informed consent * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly. * Agreement to be followed up at a TRACERx EVO site Cohort A: * Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery * Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre) * Primary surgery in keeping with NICE guidelines (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection) * For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter of at least 15mm on imaging to allow for tissue sampling of at least two tumour regions; this can either be two fresh tissue samples or one fresh tissue sample plus one representative diagnostic FFPE block (to be requested at a later date according…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.